Praxis Precision Medicines to Present at Two February Investor Conferences

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates [3] Upcoming Events - The company will participate in the Guggenheim Securities SMID Cap Biotechnology Conference on February 6, 2025, at 2:30 p.m. EST, featuring a fireside chat [4] - Additionally, Praxis will take part in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 11:20 a.m. EST, also featuring a fireside chat [4] - Both events will have live webcasts available, and replays will be accessible for 90 days on the company's website [2]